Sandoz Launches Biosimilar Pyzchiva® Across Europe to Treat Chronic Inflammatory Diseases
Sandoz, the global leader in generic and biosimilar medicines, has announced the launch of Pyzchiva® (ustekinumab) across Europe, marking a significant advancement in the...
Macular Degeneration Treatment Advances as Sandoz Receives FDA Approval for Enzeevu™
Sandoz, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) has approved Enzeevu™ (aflibercept-abzv) for neovascular...
Biosimilars Receives Landmark Approval from European Commission
Biosimilars Wyost® and Jubbonti® have received landmark approval from the European Commission (EC), marking the first biosimilar versions of denosumab to be authorized in...
The FDA has approved two interchangeable denosumab biosimilars in managing primary and secondary bone loss, denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti), developed by Sandoz and...
A Breakthrough Biosimilar as Disease-Modifying Therapy for Multiple Sclerosis Treatment
MAT -
Tyruko has been indicated as a single disease-modifying therapy (DMT) for adults diagnosed with highly active Relapsing-Remitting Multiple Sclerosis (RRMS), a designation also approved...
Novartis Has Completed The Spin-Off of Sandoz, Its Generics and Biosimilars Division
MAT -
Novartis successfully carried out the Sandoz Spin-off, marking the conclusion of its strategic transformation into prominent pharmaceuticals. This separation was executed through a dividend-in-kind...
